Lucent Diagnostics

Pre-clinical

San Diego, United StatesFounded 2020lucentdiagnostics.com

Lucent Diagnostics is dedicated to transforming Alzheimer's detection and diagnosis by making highly-sensitive, accessible blood tests the new standard of care. Its core offerings are the LucentAD® Complete and LucentAD® p-Tau217 tests, which utilize the ultrasensitive Simoa® platform to identify Alzheimer's-related biomarkers. As a commercial-stage diagnostics brand under the publicly-traded Quanterix Corporation, it aims to empower healthcare providers with tools for earlier intervention and improved patient outcomes in the rapidly evolving Alzheimer's therapeutic landscape.

Founded

2020

Focus

Diagnostics

AI Company Overview

Technology Platform

Utilizes Quanterix's proprietary Simoa® (Single Molecule Array) technology, a digital immunoassay platform that provides ultra-sensitive detection of protein biomarkers in blood, enabling measurement of neurological markers at clinically relevant levels.

Funding History

Total raised: $3.5M

Seed$3.5MUndisclosedMay 15, 2022

Opportunities

Significant growth is driven by the rollout of new Alzheimer's therapies requiring companion diagnostics, the large unmet need for scalable early detection tools, and the potential to expand the Simoa® platform into monitoring treatment response and other neurodegenerative conditions like Parkinson's and ALS.

Risk Factors

Key risks include navigating the uncertain regulatory pathway for Laboratory Developed Tests (LDTs), securing widespread insurance reimbursement, achieving rapid clinical adoption against established and emerging competitors, and executing the commercial strategy effectively as a brand within a larger parent company.

Competitive Landscape

Faces competition from C2N Diagnostics, large reference labs (Quest, Labcorp), and pharmaceutical companies (Roche, Eli Lilly) developing blood-based Alzheimer's tests. Lucent's primary differentiation is the ultra-sensitive Simoa® technology platform, which is specifically designed for detecting low-abundance neurological biomarkers in blood.